Therapeutic efficacy of entecavir combined with Liuweiwuling tablets in 41 patients with chronic hepatits B

Objective To evaluate the efficacy and safety of entecavir combined with Liuweiwuling tablets in the treatment of chronic hepatitis B(CHB). Methods A total of 81 CHB outpatients or hospitalized patients treated in our hospital from Jul. 2010 to Jul. 2011 were randomly divided into a combination group(n =41) and a control group(n =40). The combination group was treated with entecavir combined with Liuweiwuling tablets, while the control group was given entecavir alone. Clinical symptoms, signs and adverse reactions were recorded monthly during the treatment, and HBsAg, HBeAg, HBV DNA, blood routine and liver-kidney function were detected before treatment and at 3-, 6- and 12-month of treatment, respectively. Results The HBeAg negative conversion rate, HBeAb positive conversion rate, HBV DNA negative conversion rate and ALT normalization rate of the combination group were significantly higher than those of the control group, and the differences between the two groups were significant. No allergic reaction and kidney injury were found in the two groups. Dizziness, abdominal discomfort and other adverse reactions occurred in one patient in the combination group and 2 patients in the control group, but had no effect on the treatment. Conclusions Entecavir combined with Liuweiwuling tablets can quickly and effectively suppress HBV replication in CHB patients. The combination medication is safe and well tolerated. The therapeutic efficacy of entecavir combined with Liuweiwuling tablets is better than that of entecavir alone, but needs further study to verify.